• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, September 16, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Joseph Moskal elected to medical and biological engineering elite

Bioengineer by Bioengineer
February 14, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Sally Ryan

Northwestern University's Joseph R. Moskal has been elected to the American Institute for Medical and Biological Engineering's (AIMBE) College of Fellows. Moskal was cited for his studies of the NMDA receptor, which have led to the design and development of novel therapeutics for the treatment of depression.

Moskal, a distinguished research professor in Northwestern's Department of Biomedical Engineering, is among 145 engineers who make up the College of Fellows Class of 2017. They will be inducted during AIMBE's 2017 annual meeting on March 20 in Washington, D.C.

The College of Fellows comprises the top two percent of medical and biological engineers in the country. Current AIMBE Fellows have received some of the nation's highest awards, including the Presidential Medal of Science and Presidential Medal of Technology and Innovation. Many are also members of the National Academy of Engineering, National Academy of Medicine, and National Academy of Sciences.

"I am honored to join such an elite group of engineers," said Moskal, founding director of Northwestern's Falk Center for Molecular Therapeutics. "I hope this will help motivate the next generation to continue to develop what we have only begun to understand."

Moskal founded and served as chief scientific officer of Naurex, Inc., a drug discovery company that develops therapies for difficult-to-treat depression and other central nervous system diseases. While at Naurex, his team developed rapastinel, a novel therapy for treatment-resistant major depression, which is now in phase III clinical trials. In 2015, Allergan acquired Naurex for $1.7 billion.

Now, Moskal is the co-founder of Aptinyx, Inc., which targets areas of pain, post-traumatic stress disorder, and traumatic brain injury for therapeutic development. Last year, he was inducted into the National Academy of Inventors and the Chicago Area Entrepreneurship Hall of Fame.

###

Media Contact

Megan Fellman
[email protected]
847-491-3115
@northwesternu

http://www.northwestern.edu

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Exploring Food-Environment Links in Catchment Models

Exploring Food-Environment Links in Catchment Models

September 16, 2025
PPARγ Drives OSCC Growth Through Th17 and CEBPA

PPARγ Drives OSCC Growth Through Th17 and CEBPA

September 16, 2025

Access and Need Influence COPD Care Decisions

September 16, 2025

Leading Cancer Societies Revise Clinical Guidelines for Post-Mastectomy Radiation Therapy

September 16, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    154 shares
    Share 62 Tweet 39
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    117 shares
    Share 47 Tweet 29
  • Physicists Develop Visible Time Crystal for the First Time

    66 shares
    Share 26 Tweet 17
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Exploring Food-Environment Links in Catchment Models

PPARγ Drives OSCC Growth Through Th17 and CEBPA

Access and Need Influence COPD Care Decisions

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.